pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

carisma-therapeutics PRESS RELEASE ARCHIVE

Mar 7, 2023

Carisma Therapeutics Closes Merger with Sesen Bio

Feb 7, 2023

Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board

Jan 31, 2023

Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

Dec 29, 2022

Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

Nov 11, 2022

Carisma Therapeutics Announces Clinical and Pre-Clinical Updates

Nov 1, 2022

Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting

Oct 26, 2022

Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences

Jun 27, 2022

Steven Kelly, President and CEO of Carisma Therapeutics, Named Ernst and Young Entrepreneur of the Year 2022 Greater Philadelphia

May 26, 2022

Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting

Apr 25, 2022

Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer

Apr 8, 2022

Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting

Dec 6, 2021

Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA (pembrolizumab) in a Clinical Study

Nov 29, 2021

Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors

Nov 12, 2021

Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage

Sep 22, 2021

CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

Jun 8, 2021

CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer

Apr 28, 2021

CARISMA Therapeutics to Present Data at The American Society of Gene and Cell Therapy 24th Annual Meeting

Apr 26, 2021

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

Apr 9, 2021

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

Mar 18, 2021

CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

Mar 1, 2021

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

Jan 7, 2021

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

Oct 8, 2020

CARISMA Therapeutics to Present at Upcoming Healthcare Industry Conferences

Oct 5, 2020

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

Aug 25, 2020

CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

Jul 30, 2020

CARISMA Therapeutics to Participate in Upcoming Investor Conferences

Jul 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

May 21, 2020

Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences

Feb 28, 2020

Carisma Therapeutics to Present at March Scientific and Investor Conferences

Jan 6, 2020

Carisma Therapeutics Expands Leadership with Appointments of Debora Barton as Chief Medical Officer and Tom Wilton as Chief Business Officer

Nov 16, 2019

Carisma Therapeutics Announces Investor Conference Participation

Sep 9, 2019

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

Jun 3, 2019

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Mar 5, 2019

Carisma Therapeutics Announces Upcoming Conference Participation

Jun 27, 2018

Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy

Google Analytics Alternative